labetalol has been researched along with Brain Neoplasms in 3 studies
Labetalol: A salicylamide derivative that is a non-cardioselective blocker of BETA-ADRENERGIC RECEPTORS and ALPHA-1 ADRENERGIC RECEPTORS.
labetalol : A diastereoisomeric mixture of approximately equal amounts of all four possible stereoisomers ((R,S)-labetolol, (S,R)-labetolol, (S,S)-labetalol and (R,R)-labetalol). It is an adrenergic antagonist used to treat high blood pressure.
2-hydroxy-5-{1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl}benzamide : A member of the class of benzamides that is benzamide substituted by a hydroxy group at position 2 and by a 1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl group at position 5.
Brain Neoplasms: Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We compared the efficacy of the combination of enalaprilat/labetalol with that of enalaprilat/nicardipine to prevent emergence postcraniotomy hypertension." | 9.09 | A comparative study between a calcium channel blocker (Nicardipine) and a combined alpha-beta-blocker (Labetalol) for the control of emergence hypertension during craniotomy for tumor surgery. ( Broad, C; Ferri, E; Kross, RA; Leung, D; Melendez, JA; Pratila, M; Veronesi, M, 2000) |
| "We compared the efficacy of the combination of enalaprilat/labetalol with that of enalaprilat/nicardipine to prevent emergence postcraniotomy hypertension." | 5.09 | A comparative study between a calcium channel blocker (Nicardipine) and a combined alpha-beta-blocker (Labetalol) for the control of emergence hypertension during craniotomy for tumor surgery. ( Broad, C; Ferri, E; Kross, RA; Leung, D; Melendez, JA; Pratila, M; Veronesi, M, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (66.67) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Montolivo, M | 2 |
| Gemma, M | 2 |
| Regi, B | 2 |
| Coffano, B | 1 |
| Giannini, A | 1 |
| Grandi, L | 1 |
| Fiacchino, F | 2 |
| Kross, RA | 1 |
| Ferri, E | 1 |
| Leung, D | 1 |
| Pratila, M | 1 |
| Broad, C | 1 |
| Veronesi, M | 1 |
| Melendez, JA | 1 |
| Pastore, JC | 1 |
| Bricchi, M | 1 |
| Vescovi, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Efficiency of Intravenous Lidocaine to Reduce Coughing and the Hemodynamic Changes Associated to Tracheal Extubation[NCT03731429] | Phase 4 | 144 participants (Anticipated) | Interventional | 2019-04-05 | Recruiting | ||
| Nicardipine Versus Esmolol for Management of Emergence Hypertension After Craniotomy[NCT01951950] | Phase 1 | 40 participants (Actual) | Interventional | 2013-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT01951950)
Timeframe: 1 hour postoperatively
| Intervention | participants (Number) |
|---|---|
| Nicardipine | 1 |
| Esmolol | 11 |
1 trial available for labetalol and Brain Neoplasms
2 other studies available for labetalol and Brain Neoplasms
| Article | Year |
|---|---|
Labetalol as prophylaxis of cardiovascular instability after cerebral angioma surgery.
Topics: Brain Neoplasms; Epinephrine; Hemangioma; Humans; Hypertension; Labetalol; Norepinephrine; Postopera | 1993 |
[Labetalol in the prophylaxis of postoperative arterial hypertension in surgery of the posterior cranial fossa].
Topics: Adolescent; Adult; Aged; Brain Neoplasms; Cranial Fossa, Posterior; Female; Humans; Hypertension; La | 1992 |